Dr.ย Hyun Cheolย Chung
MD, PhD
Professor & Director, Yonsei Cancer Center
corporate_fareYonsei University Health System / Severance Hospital, Seoul
Hyun Cheol Chung
MD, PhD
Prof. Hyun Cheol Chung is a Professor of Medical Oncology and Director of Yonsei Cancer Center at Yonsei University College of Medicine and Severance Hospital in Seoul, South Korea. He is one of the most internationally recognised medical oncologists in gastrointestinal oncology, with over 25 years of clinical and research experience focused on gastric cancer, HER2-positive tumours, and immuno-oncology.
Prof. Chung has been a principal investigator and key contributor to landmark gastric cancer trials including the ToGA study, which established trastuzumab as standard of care for HER2-positive advanced gastric cancer, and KEYNOTE-811, which evaluated pembrolizumab plus trastuzumab and chemotherapy in HER2-positive disease. He has served as corresponding author on major phase III studies including KEYNOTE-063, comparing pembrolizumab and paclitaxel in Asian patients with advanced gastric and gastroesophageal junction cancer. His research spans HER2-targeted therapy, PD-1/PD-L1 immunotherapy, biomarker-driven treatment selection, and translational oncology. Prof. Chung is also associated with the Song Dang Institute for Cancer Research and the Brain Korea 21 PLUS Project for Medical Science, reflecting his deep ties to translational gastric cancer research.
CancerFax can coordinate medical record review, case preparation, and consultation support for international patients seeking an opinion from specialists at Yonsei Cancer Center.
Why Consider Prof. Hyun Cheol Chung?
Prof. Chung is a globally recognised authority in gastric cancer with a strong clinical trial record, leadership of Yonsei Cancer Center, and a research profile that has directly shaped international treatment standards for HER2-positive and immunotherapy-eligible gastric cancer.
Areas of Specialisation
Advanced gastrointestinal oncology, HER2-targeted therapy, and immunotherapy for gastric and related GI cancers
Prof. Chung's clinical practice is focused on advanced gastric cancer, HER2-positive disease, gastroesophageal junction cancer, and oesophageal adenocarcinoma, with a strong emphasis on biomarker-driven systemic therapy and clinical trial access.
HER2-Targeted Therapy for Gastric Cancer
Evidence-based HER2-directed treatment for advanced and metastatic gastric cancer patients with confirmed HER2 overexpression or amplification.
- arrow_rightFirst-line trastuzumab plus chemotherapy for HER2-positive advanced gastric cancer
- arrow_rightTreatment selection guided by HER2 testing (IHC and FISH/ISH)
- arrow_rightCombination regimens incorporating targeted agents with chemotherapy backbones
- arrow_rightAntibody-drug conjugate strategies including trastuzumab deruxtecan in previously treated patients
- arrow_rightBiomarker assessment for HER2 re-testing at disease progression
- arrow_rightResistance mechanisms and treatment sequencing after HER2-targeted therapy
Immunotherapy & Checkpoint Inhibition
Integration of PD-1 and PD-L1 inhibitors into gastric cancer treatment based on biomarker selection and clinical evidence from major phase III trials.
- arrow_rightPembrolizumab and nivolumab in PD-L1 positive and selected gastric cancer populations
- arrow_rightBiomarker selection using CPS, MSI/MMR status, and tumour mutational burden
- arrow_rightFirst-line and second-line immunotherapy strategies for advanced gastric cancer
- arrow_rightPembrolizumab plus trastuzumab and chemotherapy for HER2-positive advanced gastric cancer (KEYNOTE-811 approach)
- arrow_rightCombination regimens under investigation in clinical trial settings
Advanced Gastric & GI Oncology
Comprehensive medical oncology for advanced and metastatic gastrointestinal cancers, with expertise in systemic therapy, treatment planning, and clinical trial enrolment.
- arrow_rightFirst-line chemotherapy regimens including XELOX, FOLFOX, and platinum-fluoropyrimidine combinations
- arrow_rightTreatment sequencing for refractory or relapsed disease
- arrow_rightMultidisciplinary tumour board review and case-based treatment planning
- arrow_rightSystemic therapy for GEJ adenocarcinoma with overlapping gastric cancer protocols
- arrow_rightBiomarker testing including HER2, PD-L1 CPS, CLDN18.2, FGFR2b, and MSI
Clinical Services & Procedures
Systemic therapy, biomarker-guided treatment, and clinical trial participation for advanced gastric and GI cancers
Prof. Chung provides evidence-based systemic oncology care for patients with advanced gastric cancer and related GI malignancies, with expertise in HER2-targeted therapy, immunotherapy, chemotherapy, and enrolment into clinical trials.
Medical Oncology โ Gastric Cancer
Medical OncologyComprehensive systemic treatment planning for patients with advanced or metastatic gastric and gastroesophageal junction cancer.
Targeted Therapy & Biomarker-Guided Selection
Targeted TherapyMolecularly guided treatment planning based on HER2, PD-L1, MSI, and other genomic and protein biomarkers.
Clinical Trial Access
MultidisciplinaryAccess to investigational treatment protocols for eligible patients through Yonsei Cancer Center's active clinical trials programme.
Second Opinion & Complex Case Review
Second OpinionExpert second opinion for patients with complex, refractory, or newly diagnosed advanced gastric cancer requiring specialised review.
Research & Publications
Landmark gastric cancer trials and peer-reviewed contributions to GI oncology
Prof. Chung has authored and co-authored extensively in gastric cancer, HER2-targeted therapy, and immunotherapy. His research has directly influenced global treatment guidelines and shaped the current standard of care for advanced gastric and gastroesophageal junction cancer.
Prof. Chung's publications have accumulated over 3,500 citations. A full publication list is available on PubMed and ResearchGate.
Education & Training
Prof. Chung completed his medical training at Yonsei University College of Medicine and subsequently undertook advanced research fellowships in the United States and Europe, building the international oncology network that underpins his clinical trial leadership.
Clinical Experience
Prof. Chung has built his entire career at Yonsei University Health System, rising to become Director of Yonsei Cancer Center and a globally recognised leader in gastrointestinal oncology and clinical drug development.
Languages & International
Prof. Chung consults in the following languages.
CancerFax can arrange professional medical interpreter support for international patients requiring consultation assistance beyond English and Korean.
CancerFax can coordinate professional medical interpreter support for patients consulting in other languages.
How CancerFax Helps You Access Dr. Hyun Cheol Chung
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Hyun Cheol Chung's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Hyun Cheol Chung's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Hyun Cheol Chung before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Hyun Cheol Chung's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Hyun Cheol Chung's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Hyun Cheol Chung's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Hyun Cheol Chung
Prof. Hyun Cheol Chung is a Professor of Medical Oncology and Director of Yonsei Cancer Center at Yonsei University College of Medicine and Severance Hospital in Seoul, South Korea. He is one of the world's leading clinical oncologists in gastric cancer, HER2-targeted therapy, and immunotherapy, with over 25 years of experience and a major role in shaping global treatment standards through landmark clinical trials.
Prof. Chung specialises primarily in advanced gastric cancer, HER2-positive gastric cancer, gastroesophageal junction cancer, and oesophageal adenocarcinoma. He also has research experience in colorectal cancer. His practice emphasises biomarker-driven treatment planning including HER2 testing, PD-L1 assessment, MSI/MMR status, and genomic profiling to guide systemic therapy decisions.
Prof. Chung is internationally recognised for his role as principal investigator and corresponding author on pivotal gastric cancer trials. He was a key contributor to the ToGA trial, which established trastuzumab for HER2-positive advanced gastric cancer, and led KEYNOTE-811, which evaluated pembrolizumab plus trastuzumab and chemotherapy in this setting. He also led KEYNOTE-063, comparing pembrolizumab and paclitaxel as second-line therapy in Asian patients with advanced gastric cancer.
International patients may seek consultation or a second opinion through Yonsei University Health System's international patient services or through CancerFax. CancerFax can assist with medical record review, case preparation, and coordination of the consultation request with the hospital, subject to availability and case acceptance.
A second opinion request can be submitted through CancerFax with the patient's complete medical file including pathology reports, imaging, HER2 testing results, prior treatment records, and blood work. The CancerFax team will review the documents, prepare the case summary, and coordinate with Yonsei Cancer Center regarding the consultation format and availability.
Yonsei Cancer Center has an active clinical trials programme in gastric and gastrointestinal oncology. International patients with advanced or refractory gastric cancer may be eligible for investigational treatment studies depending on their diagnosis, biomarker profile, prior treatment history, and performance status. CancerFax can assist with the initial eligibility review process.
Connect with Hyun Cheol Chung Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.